S&P 500
7,507.80
-0.22%
Dow Jones
51,595.40
-0.32%
Nasdaq 100
30,411.80
-0.23%
Russell 2000
2,975.48
-0.09%
FTSE 100
10,384.80
-0.34%
Nikkei 225
71,987.20
+0.02%

Investing

SciClone Cancels Development of New Drug (SCLN)

Photo of Paul Ausick
By Paul Ausick Published

Specialty drug maker SciClone Pharmaceuticals Inc. (NASDAQ: SCLN) announced this morning that the company will “discontinue development” of its SCV-07 oral mucositis drug because the drug failed to “meet the pre-specified efficacy endpoints” of the phase 2b trials.

From the company’s announcement:

SciClone is notifying the FDA and study investigators of the trial’s discontinuation. No additional patients will be enrolled in the trial. Dosing of subjects currently enrolled in the trial will be discontinued, but subjects will be followed per protocol for a full year.

The company noted that there were no safety issues with SCV-07. The drug simply did not do what it was intended to do.

SciClone’s shares closed at $4.52 yesterday, in a 52-week range of $3.30-$6.88.

Follow 24/7 Wall St. on Google
Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Why Clovis Bladder Cancer Treatment Rucaparib Is in Big Trouble
Chris Lange |

Why Clovis Bladder Cancer Treatment Rucaparib Is in Big Trouble

Clovis Oncology may have thought that it could sneak an announcement by late on Friday, but its shares were definitely…

Celgene Faces Multiple Clinical Holds From FDA
Chris Lange |

Celgene Faces Multiple Clinical Holds From FDA

Celgene received an update from the FDA early on Thursday. Although shares did not dip initially, this action could prove…

5 FDA COVID-19 Decisions in July Could Make or Break Stocks
Chris Lange |

5 FDA COVID-19 Decisions in July Could Make or Break Stocks

Here is a look of a few of the biggest clinical trial and FDA updates to watch for in July…

Chris Lange |

4 New Big FDA Decisions Expected in September

24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of September and…

Massive Biopharma Movers of the Past Week
Chris Lange |

Massive Biopharma Movers of the Past Week

A few biopharma stocks made massive runs over the course of this past week, some losing more than half their…

Can Epizyme Survive This FDA Hold?
Chris Lange |

Can Epizyme Survive This FDA Hold?

Epizyme shares tumbled on Tuesday after the FDA announced a partial clinical hold affecting new enrollment of patients in the…

Key FDA Decisions and Trial Results Coming in the Next 2 Months
Chris Lange |

Key FDA Decisions and Trial Results Coming in the Next 2 Months

24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in…

AstraZeneca Cuts Almost All Ties to Inovio Pharma
Chris Lange |

AstraZeneca Cuts Almost All Ties to Inovio Pharma

Inovio Pharmaceuticals shares dipped on Wednesday after it was announced that the firm’s partnership with AstraZeneca would be scaled back.

Corbus Pharmaceuticals Skyrockets on Positive Mid-Stage Results
Chris Lange |

Corbus Pharmaceuticals Skyrockets on Positive Mid-Stage Results

Corbus Pharmaceuticals shares skyrocketed on Monday morning after the company announced positive results from its mid-stage clinical trial in systemic…

Top Gaining Stocks

CarMax
KMX • Vol: 7,330,419
Corning
GLW • Vol: 22,800,969
Intel
INTC • Vol: 233,719,006
Super Micro Computer
SMCI • Vol: 68,465,534
Enphase Energy
ENPH • Vol: 13,978,376

Top Losing Stocks

Accenture
ACN • Vol: 41,744,333
EPAM Systems
EPAM • Vol: 5,636,587
Cognizant
CTSH • Vol: 61,311,400
Coterra Energy
CTRA • Vol: 73,319,495
Kroger
KR • Vol: 26,704,230